12:15 EDT Ionis Pharmaceuticals (IONS) trading resumes
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals announces FDA approval of Dawnzera
- Ionis Pharmaceuticals trading halted, news pending
- Promising Prospects for Ionis Pharmaceuticals: Buy Rating Backed by Olezarsen’s Potential in sHTG Market
- Ionis Pharmaceuticals price target raised to $46 from $45 at UBS
- Positive Outlook for Ionis Pharmaceuticals Driven by Strong Q2 Results and Promising Pipeline Developments